Banu K. Arun
A5015127974- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Nutrition, Genetics, and Disease
- DNA Repair Mechanisms
- Genetic factors in colorectal cancer
- Estrogen and related hormone effects
- Ovarian cancer diagnosis and treatment
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Risks and Factors
- Genetic Associations and Epidemiology
- Genomics and Rare Diseases
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Genomic variations and chromosomal abnormalities
- Metabolism, Diabetes, and Cancer
- Breast Lesions and Carcinomas
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Molecular Biology Techniques and Applications
- Cancer survivorship and care
The University of Texas MD Anderson Cancer Center
2015-2024
Cancer Genetics (United States)
2015-2024
The University of Texas Southwestern Medical Center
2000-2024
Vaidyaratnam P.S. Varier Ayurveda College
2024
Breast Cancer Care
2005-2023
Breast Cancer Research Foundation
2023
The University of Texas Health Science Center at Houston
2021-2023
Institute of Cancer Research
2019
Tata Medical Center
2017-2018
Centro de Investigación Biomédica en Red
2018
Purpose The objective of this study was to determine whether the addition trastuzumab chemotherapy in neoadjuvant setting could increase pathologic complete response (pCR) rate patients with human epidermal growth factor receptor 2 (HER2) –positive disease. Patients and Methods Forty-two HER2-positive disease operable breast cancer were randomly assigned either four cycles paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide or same simultaneous weekly for 24 weeks. primary...
The American Society of Clinical Oncology (ASCO) has long affirmed that the recognition and management individuals with an inherited susceptibility to cancer are core elements oncology care. ASCO released its first statement on genetic testing in 1996 updated 2003 2010 response developments field. In 2014, Cancer Prevention Ethics Committees commissioned another update reflect impact advances this area practice. particular, there was interest addressing opportunities challenges arising from...
Purpose: To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, determine blockade of potentiates inhibitor (PARPi) in tumor suppression.Experimental Design: Breast cancer cell lines, xenograft tumors, syngeneic tumors treated with PARPi were assessed for PD-L1 expression by immunoblotting, IHC, FACS analyses. The phospho-kinase antibody array screen was used to the underlying mechanism PARPi-induced upregulation. therapeutic efficacy alone, or...
Mutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. We determined whether tumor pathologic features clinical differ patients with without BRCA mutations.Tumor characteristics were examined 491 women cancer who underwent genetic testing for mutations between 1997 2006. A retrospective review medical records was conducted to determine including ethnicity, age stage at diagnosis, parity, number full-term pregnancies, use oral contraceptives hormone...
PURPOSE: To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2–overexpressing metastatic breast cancer. Efficacy was correlated serum HER-2 extracellular domain (ECD) levels. PATIENTS AND METHODS: Thirty cancer were treated as first- or second-line therapy. Both 35 mg/m 2 /wk mg/kg/wk delivered 4-week cycles consisting three treatments followed by 1 week rest. A loading dose 4 mg/kg administered day before start first cycle. RESULTS: The median...
Purpose The goal of this study was to examine the feasibility developing a multigene predictor pathologic complete response (pCR) sequential weekly paclitaxel and fluorouracil + doxorubicin cyclophosphamide (T/FAC) neoadjuvant chemotherapy regimen for breast cancer. Patients Methods All patients underwent one-time pretreatment fine-needle aspiration obtain RNA from cancer transcriptional profiling using cDNA arrays containing 30,721 human sequence clones. Analysis performed after profiling,...
To investigate the incidence of germline and somatic BRCA1/2 mutations in unselected patients with triple-negative breast cancer (TNBC) determine prognostic significance carrying a mutation.DNA was obtained from 77 TNBC normal tissues. exons/flanking regions were sequenced tumor classified as mutant or wild type (WT). Sequencing repeated tissue to identify mutations. Patient characteristics compared chi-square. Survival estimated by Kaplan-Meier method log-rank. Cox proportional hazards...
BACKGROUND Previous studies have reported additional cancers associated with BRCA mutations; however, the type, magnitude of risk, and sex differences remain to be clarified. The purpose this study was evaluate incidence other than breast ovarian cancer in known mutation carriers. METHODS An institutional review board–approved identified 1072 patients who had genetic counseling at authors' institution tested positive for a deleterious mutation. expected number cases calculated from...
Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists.
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with 1,839 cancer), replication in an additional sample 2,646 carriers. We identified novel risk modifier locus at 1q32 for (rs2290854, P = 2.7×10−8, HR 1.14, 95% CI: 1.09–1.20). In addition, two loci: 17q21.31 (rs17631303, 1.4×10−8, 1.27, 1.17–1.38) 4q32.3 (rs4691139,...
There is limited prognostic information to identify breast cancer patients who are at risk for late recurrences after adjuvant or neoadjuvant systemic therapy (AST). We evaluated the residual of recurrence and factors 2838 with stage I–III were treated AST between January 1, 1985, November 2001, remained disease free 5 years. Residual recurrence-free survival was estimated from landmark years date first last follow-up using Kaplan–Meier method. The log-rank test (two-sided) used compare...
Purpose To update the 2002 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction. Methods A literature search identified relevant randomized trials published since 2002. Primary outcome interest was BC incidence (invasive and noninvasive). Secondary outcomes included mortality, adverse events, net health benefits. An expert panel reviewed developed updated consensus guidelines. Results Seventeen articles met inclusion criteria....
Purpose Previous research incorporating yoga (YG) into radiotherapy (XRT) for women with breast cancer finds improved quality of life (QOL). However, shortcomings in this limit the findings. Patients and Methods stages 0 to III were recruited before starting XRT randomly assigned YG (n = 53) or stretching (ST; n 56) three times a week 6 weeks during waitlist (WL; 54) control. Self-report measures QOL (Medical Outcomes Study 36-item short-form survey; primary outcomes), fatigue, depression,...
Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months a known germline BRCA pathogenic variant (gBRCA-positive) and operable cancer.Eligibility included 1 cm or larger invasive tumor gBRCA-positive disease. Human epidermal growth factor receptor 2-positive tumors were excluded. Twenty underwent pretreatment biopsy, once per day oral (1 mg), followed by definitive surgery....
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk breast, ovarian, pancreatic, prostate cancer, including BRCA1 , BRCA2 CDH1 PALB2 PTEN TP53 recommended approaches to genetic counseling/testing care strategies in individuals these P/LP variants. These Insights summarize important updates regarding: (1) a new section transgender, nonbinary...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following guideline development process as outlined in Methodology Manual . follow Conflict Interest Policy Clinical Practice other guidance (“Guidance”) provided by is not a or definitive guide to treatment options. It intended voluntary use providers should be used conjunction independent professional judgment. Guidance may applicable all patients,...